Open AccessKatanin P80 correlates with larger tumor size, lymph node metastasis, and advanced TNM stage and predicts poor prognosis in non–small‐cell lung cancer patients
Author(s) -
Ye Qing,
Zhang Min,
Yin Yiping
Publication year - 2020
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.23141
Subject(s) - medicine , stage (stratigraphy) , oncology , lung cancer , pathology , biology , paleontology
Objective The present study aimed to investigate the correlation of katanin P80 expression with clinicopathological features and survival profile in non–small‐cell lung cancer (NSCLC) patients. Methods Totally, 398 NSCLC patients treated by pulmonary resection were enrolled and their tumor specimens were collected to determine katanin P80 expression by immunohistochemistry (IHC) assay. Clinical data were collected at diagnosis, and survival data including disease‐free survival (DFS) and overall survival (OS) were assessed after treatment. Results There were 195 (49.0%) patients with katanin P80 high expression and 203 (51.0%) patients with katanin P80 low expression, respectively. Meanwhile, katanin P80 high expression was associated with larger tumor size ( P = .001), lymph node (LYN) metastasis ( P = .005), and advanced TNM stage ( P = .001). As for survival data, katanin P80 high expression was correlated with reduced DFS ( P < .001) and OS ( P < .001). And forward stepwise multivariate Cox's regression revealed that katanin P80 high expression was an independent predictor for decreased DFS ( P < .001) and OS ( P < .001). Besides, further analysis indicated that DFS ( P < .001) and OS ( P < .001) were the shortest in patients with katanin P80 high+++ expression, followed by patients with katanin P80 high++ expression and then those with katanin P80 high + expression and katanin P80 low expression. Conclusion Katanin P80 correlates with larger tumor size, LYN metastasis, and advanced TNM stage, and serves as a potential biomarker for predicting poor survival in NSCLC patients.